StreetInsider.com News Articles

Form 8-K ELUTIA INC. For: Jul 16

Mon, 20 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260720/26789745.html

Form 8-K ELUTIA INC. For: Jul 16

Mon, 20 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260720/26789745.html

Elutia agrees to sell SimpliDerm unit for up to $11 million

Thu, 16 Jul 2026 16:05:29 -0400

Elutia Inc. (Nasdaq: ELUT) has signed a definitive agreement to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million, according to a company press release.

Under the terms of the deal, Elutia will receive $8 million in cash at closing, with up to an additional $3 million in technology transfer and commercial milestone payments over the following 18 months. Closing is expected in the second half of 2026, subject to customary conditions.

The company said proceeds will be used to advance its NXT-41x antibiotic-eluting biomatrix product, which is targeted at the

Elutia agrees to sell SimpliDerm unit for up to $11 million

Thu, 16 Jul 2026 16:05:29 -0400

The company said proceeds will be used to advance its NXT-41x antibiotic-eluting biomatrix product, which is targeted at the

Elutia agrees to sell SimpliDerm unit for up to $11 million

Thu, 16 Jul 2026 16:05:29 -0400

The company said proceeds will be used to advance its NXT-41x antibiotic-eluting biomatrix product, which is targeted at the

Elutia agrees to sell SimpliDerm unit for up to $11 million

Thu, 16 Jul 2026 16:05:29 -0400

The company said proceeds will be used to advance its NXT-41x antibiotic-eluting biomatrix product, which is targeted at the

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Thu, 16 Jul 2026 16:05:00 -0400

Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 months
Proceeds provide additional non-dilutive capital to advance NXT-41x toward anticipated clearance and targeted commercial launch in 2027
Divestiture sharpens Elutia’s focus on NXT-41x and the $1.5 billion plastic and reconstructive surgery opportunity

GAITHERSBURG, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the signing of a definitive agreement to sell its SimpliDerm® human acellular dermal matrix

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Thu, 16 Jul 2026 16:05:00 -0400

Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 months
Proceeds provide additional non-dilutive capital to advance NXT-41x toward anticipated clearance and targeted commercial launch in 2027
Divestiture sharpens Elutia’s focus on NXT-41x and the $1.5 billion plastic and reconstructive surgery opportunity

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Thu, 16 Jul 2026 16:05:00 -0400

Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 months
Proceeds provide additional non-dilutive capital to advance NXT-41x toward anticipated clearance and targeted commercial launch in 2027
Divestiture sharpens Elutia’s focus on NXT-41x and the $1.5 billion plastic and reconstructive surgery opportunity

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Thu, 16 Jul 2026 16:05:00 -0400

Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 months
Proceeds provide additional non-dilutive capital to advance NXT-41x toward anticipated clearance and targeted commercial launch in 2027
Divestiture sharpens Elutia’s focus on NXT-41x and the $1.5 billion plastic and reconstructive surgery opportunity

Form 4 ELUTIA INC. For: Jun 21 Filed by: Mills C Randal

Mon, 22 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260622/26673962.html

Form 4 ELUTIA INC. For: Jun 21 Filed by: Mills C Randal

Mon, 22 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260622/26673962.html

Form 8-K ELUTIA INC. For: Jun 11

Tue, 16 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260616/26655047.html

Form 8-K ELUTIA INC. For: Jun 11

Tue, 16 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260616/26655047.html

Form 4 ELUTIA INC. For: Jun 11 Filed by: Colpman David